King-Jones Heidy Insider Trading -- Recent SEC Form 4 Transactions
King-Jones Heidy (CIK 1794898) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-10-02). Recent activity: Sell SYRE (400 shares), Sell SYRE (16,605 shares), Sell SYRE (7,228 shares), Sell SYRE (2,100 shares), Sell SYRE (2,600 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Legal Officer and Corporate Secretary | Sell | 400 | $35,696 |
| 2026-10-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Legal Officer and Corporate Secretary | Sell | 16,605 | $1.5M |
| 2026-10-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Legal Officer and Corporate Secretary | Sell | 7,228 | $660,278 |
| 2026-10-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Legal Officer and Corporate Secretary | Sell | 2,100 | $194,670 |
| 2026-10-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Legal Officer and Corporate Secretary | Sell | 2,600 | $242,996 |
| 2026-10-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Legal Officer and Corporate Secretary | Buy | 28,933 | $419,528 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Sell | 6,206 | $547,183 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Buy | 27,999 | $405,986 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Sell | 4,845 | $418,608 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Sell | 16,548 | $1.4M |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Sell | 400 | $35,752 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Buy | 400 | $5,800 |
| 2026-09-03 | Spyre Therapeutics, Inc. (SYRE) | See Remarks | Sell | 400 | $36,000 |
Source: SEC Form 4 filings · as of 2026-10-02